Comparative Pharmacology
Head-to-head clinical analysis: MACROTEC versus SODIUM POLYPHOSPHATE TIN KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MACROTEC versus SODIUM POLYPHOSPHATE TIN KIT.
MACROTEC vs SODIUM POLYPHOSPHATE-TIN KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Not applicable for diagnostic use.
Sodium polyphosphate-tin kit is used for radiolabeling with technetium-99m to form Tc-99m tin colloid, which is taken up by the reticuloendothelial system (liver, spleen, bone marrow) via phagocytosis. The mechanism of action for imaging involves targeting the mononuclear phagocytic system.
5 mCi (185 MBq) intravenously as a single dose for lung perfusion imaging.
Administer intravenously as a single dose of 5-10 mCi (185-370 MBq) of technetium-99m pertechnetate combined with the kit contents, after reconstitution and labeling per manufacturer instructions.
None Documented
None Documented
6 hours; prolonged in renal impairment (up to 30 hours in ESRD)
Terminal half-life of technetium-99m pertechnetate: 6 hours (physical decay). Biological half-life of polyphosphate variable; bone-bound activity persists for days.
Renal: 95% as unchanged drug; biliary/fecal: <5% as metabolites
Renal elimination of technetium-99m pertechnetate and polyphosphate. Approximately 30% excreted in urine within 24 hours; remainder cleared via bone uptake and slow release. Fecal excretion negligible.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical